论文部分内容阅读
目的:探讨阿格列汀辅助PCI术治疗糖尿病并发冠心病对患者预后不良的影响。方法:收集来我院就诊的糖尿病并冠心病患者198例,随机分为试验组和对照组,观察两组患者预后不良影响。结果:试验组患者治疗后常见不良反应发生率和其它主要不良心脑血管事件发生率均低于对照组,分别经卡方检验比较,差异均存在统计学意义(P<0.05)。结论:阿格列汀辅助PCI术治疗糖尿病并发冠心病可有效改善患者不良预后结局。
Objective: To investigate the effect of alogliptin-assisted PCI in the treatment of diabetic patients with coronary heart disease on poor prognosis. Methods: A total of 198 patients with diabetes mellitus and coronary heart disease who were treated in our hospital were randomly divided into experimental group and control group. The adverse prognosis of the two groups was observed. Results: The incidence of common adverse reactions and other major adverse cardiac events after treatment in the experimental group were significantly lower than those in the control group. There was significant difference (P <0.05) by chi-square test. Conclusion: Alogliptin-assisted PCI in the treatment of diabetic patients with coronary heart disease can effectively improve the adverse prognosis.